<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-057JAY2R</identifier><date>2020</date><creator>Knez, Lea</creator><creator>Locatelli, Igor</creator><creator>Morgan, Tina</creator><creator>Tomšič, Tanja</creator><relation>documents/doc/0/URN_NBN_SI_doc-057JAY2R_001.pdf</relation><relation>documents/doc/0/URN_NBN_SI_doc-057JAY2R_001.txt</relation><format format_type="issue">2</format><format format_type="volume">71</format><format format_type="type">article</format><format format_type="extent">str. 121-132</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">21007107</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-057JAY2R</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">covid-19</subject><subject language_type_id="slv">favipiravir</subject><subject language_type_id="slv">hidroksiklorokin</subject><subject language_type_id="slv">lopinavir/ritonavir</subject><subject language_type_id="slv">Pandemije</subject><subject language_type_id="slv">remdesivir</subject><title>Evidence based medicine for covid-19 treatment</title><title>Z dokazi podprto zdravljenje covid-19 z zdravili</title></Record>